This page contains a Flash digital edition of a book.
INTRODUCTION


Overview


Disease background General information about both CD and UC are presented to provide a background for the average reader about these diseases. Symptoms are described, followed by currently recommended treatment options (including medications and surgeries).


Epidemiology


Epidemiology is the science that examines the patterns and occurrence of disease. This section estimates the current number of individuals in Canada with CD and UC. Other aspects of epidemiology reported include: factors associated with getting the disease; the rate at which individuals are newly diagnosed with disease; the age of people with IBD; mortality associated with IBD and a comparison of results within Canada with other geographic areas.


Direct costs Direct costs are incurred by the public health care system in Canada and include: medications, hospitalizations, surgeries, physician visits, emergency room visits, allied health care professional visits, laboratory tests and procedures, etc. The total Canadian cost was calculated by multiplying the amount that was used per person by the total number of individuals who have disease.


Indirect costs Indirect costs are incurred by individuals and society outside of the health care system. Individuals incur costs such as: non-prescription medications; travel to medical appointments; care giving and household support. Society incurs costs for worker absences and loss of productivity associated with: short and long-term disability; reduced participation in the work force and death. Workforce absences are due to the individual with disease or a caregiver of the individual with disease (such as a parent). The total Canadian cost was determined by multiplying the costs per person by the total number of individuals who have disease.


Non-financial costs


IBD has substantial impact on quality of life, and causes considerable personal, emotional and social burden. It is not well accepted to place a ‘price’ or attach a cost to this impact of IBD. Instead, information on quality of life is discussed for individuals with IBD, without determining a specific cost for the severe impact of IBD.


Conclusions and recommendations A final section was developed with two objectives: to place the Canadian experience of IBD in context with other diseases in Canada, by comparing costs for IBD from other countries and to develop a set of recommendations for the future of IBD in Canada.


THE IMPACT OF INFLAMMATORY BOWEL DISEASE IN CANADA 13


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96